Nanjing Zenshine Pharmaceuticals Co., Ltd. announced a placement of common shares for gross proceeds of CNY 60 million on September 18, 2023. The transaction will include participation from new investor, Hubei Jumpcan Pharmaceutical Co., Ltd. for 3.40520% stake. CNY 506,693 will be included in the registered capital.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
32.38 CNY | -0.92% |
|
-0.31% | +3.02% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.02% | 4.14B | |
+54.07% | 816B | |
+38.59% | 634B | |
-7.05% | 351B | |
+15.44% | 323B | |
+5.72% | 293B | |
+13.40% | 238B | |
+0.61% | 222B | |
+13.24% | 218B | |
+7.42% | 167B |
- Stock Market
- Equities
- 600566 Stock
- News Hubei Jumpcan Pharmaceutical Co., Ltd.
- Nanjing Zenshine Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 60 million in funding from Hubei Jumpcan Pharmaceutical Co., Ltd.